Cresco Labs Stock Price, News & Analysis

Cresco Labs reported a 4% year-over-year revenue growth of $218 million for Q2 2022, alongside an 11% increase in adjusted EBITDA to $51 million, reflecting resilience amid market challenges.

The company maintains its leadership as the no. 1 U.S. wholesaler of branded cannabis products, achieving a 53% adjusted gross margin.

It also noted progress in the ongoing acquisition of Columbia Care, anticipating a year-end closing. Cash on hand stood at $90 million as of June 30, 2022.

Cresco Labs (OTCQX: CRLBF), a leading U.S. wholesaler of cannabis products, has announced that Parkway Dispensary and Navāda Labs have received conditional adult-use dispensary licenses in Illinois. This follows the issuance of 185 new licenses aimed at promoting inclusivity in the cannabis industry. Cresco's SEED initiative has played a vital role in assisting social equity applicants throughout the process. Currently, Illinois has 110 dispensaries, and the new licenses will significantly increase access to cannabis products for consumers.

Cresco Labs (CSE:CL, OTCQX:CRLBF), a leading U.S. cannabis wholesaler, will announce its Q2 2022 financial results on August 17, 2022, before market opening. The company plans to hold a conference call at 8:30 AM EST to discuss the results and key business highlights. After the event, an archive of the webcast will be available for one year on the Cresco Labs investor relations website. Cresco Labs aims to normalize the cannabis industry while operating the largest social equity and educational initiative in the sector.

Cresco Labs (CSE:CL, OTCQX:CRLBF) held its annual shareholder meeting on July 15, 2022, where shareholders approved the election of 11 directors, including Charles Bachtell and Robert M. Sampson. Marcum LLP was reappointed as auditor. A significant resolution was passed regarding the company's Super Voting Shares, amending the investment agreement to facilitate a share repurchase for $800,001 after a future U.S. listing event. This decision prevents the issuance of new Super Voting Shares and mandates cancellation upon repurchase.

Columbia Care Inc. (CCHWF) has received final approval from the Supreme Court of British Columbia for its acquisition by Cresco Labs (CRLBF). This follows overwhelming shareholder support during a meeting on July 8, 2022. The CEO, Nicholas Vita, emphasized the milestone in achieving a leading position in the cannabis industry. The arrangement includes a divestiture process in key states, progressing well with strong demand from bidders. The divestitures are expected to align with the Arrangement's closing anticipated at the end of 2022.

Columbia Care (OTCQX: CCHWF) announced overwhelming shareholder support for its business combination with Cresco Labs (OTCQX: CRLBF), with 98.5% voting in favor at a special meeting held on July 8, 2022. The arrangement will see Cresco Labs acquire all issued shares of Columbia Care. A total of 169,938,646 shares were represented in the voting, constituting 42.6% of the outstanding shares. CEO Nicholas Vita expressed gratitude for the support as the company anticipates the transaction's completion by year-end.

Cresco Labs (OTCQX:CRLBF), a leading U.S. wholesaler of branded cannabis products, announced participation in key industry conferences in June 2022. Chief Commercial Officer Greg Butler will speak at the Jefferies Cannabis Summit on June 2 and CEO Charles Bachtell will engage in a fireside chat at the Oppenheimer Consumer Growth and E-Commerce Conference on June 14. Cresco is committed to normalizing the cannabis industry and operates the largest Social Equity and Educational Development initiative, SEED.

Cresco Labs reports a robust 20% year-over-year revenue growth for Q1 2022, reaching $214 million. The company also achieved a 45% increase in adjusted EBITDA, totaling $51 million. Their gross profit was $113 million (53% margin), up 29% year-over-year. Retail sales surged 44% to $119 million, averaging $2.5 million per store. Cresco maintains its market leadership in branded cannabis, despite a challenging environment. They passed the HSR review for the Columbia Care acquisition, marking a significant milestone.

Cresco Labs has announced the expiration of the 30-day waiting period under the HSR Act, a significant milestone in its acquisition of Columbia Care. CEO Charles Bachtell emphasized the benefits of leveraging Cresco's leading cannabis portfolio across a wider market, particularly in the ten states projected for substantial revenue growth by 2025. The transaction, initially detailed in March 2022, is still subject to shareholder approval and other regulatory conditions, with both companies aiming for a year-end closing. Cresco Labs ranks as the largest wholesaler of branded cannabis products in the U.S.